MYMD MyMD Pharmaceuticals, Inc.

Nasdaq tnfpharma.com


$ 3.73 $ 0.47 (14.24 %)    

Friday, 21-Nov-2025 15:44:20 EST
QQQ $ 591.16 $ 3.83 (0.65 %)
DIA $ 462.75 $ 3.28 (0.71 %)
SPY $ 659.46 $ 4.42 (0.67 %)
TLT $ 89.47 $ -0.20 (-0.22 %)
GLD $ 373.37 $ -0.59 (-0.16 %)
$ 3.28
$ 3.29
$ 3.73 x 100
$ 3.78 x 600
$ 3.29 - $ 3.88
$ 2.50 - $ 164.00
173,547
na
4.87M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-19-2025 09-30-2025 10-Q
2 08-19-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 04-11-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-19-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-01-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-18-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-16-2020 09-30-2020 10-Q
22 08-14-2020 06-30-2020 10-Q
23 05-15-2020 03-31-2020 10-Q
24 03-25-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-20-2019 03-31-2019 10-Q
28 04-01-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 07-13-2018 03-31-2018 10-Q
32 04-03-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 04-11-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system

 mymd-pharmaceuticals-announces-corporate-rebranding-to-new-name-tnf-pharmaceuticals-to-begin-under-the-new-trading-symbol-tnfa-effective-july-24-2024

New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic systemCompany plans mid-stage cl...

 latest-key-hires--board-changes-in-cannabis-industry-canopy-growth-acreage-and-more

s Benzinga Cannabis Capital Conference returns to Chicago this Oct. 8-9 its 19th edition, gathering top CEOs, investors and inv...

Core News & Articles

Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to cr...

 why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

 mymd-pharmaceuticals-filing-from-late-monday-shows-co-entered-omnibus-waiver-and-amendment-agreement-with-required-holders-under-previously-announced-securities-purchase-agreement

As previously disclosed, on February 21, 2023, MyMD Pharmaceuticals, Inc. (the "Company") entered into a Securities Pur...

 why-biophytis-shares-are-trading-higher-by-around-55-here-are-20-stocks-moving-premarket

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

 mymd-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-for-continued-listing

MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company...

 mymd-pharmaceuticals-announces-1-for-30-reverse-stock-split-to-maintain-nasdaq-listing

Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyM...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION